NASDAQ:SCYX - SCYNEXIS Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$1.93 -0.08 (-3.98 %)
(As of 07/16/2018 04:51 AM ET)
Previous Close$1.93
Today's Range$1.89 - $2.0488
52-Week Range$1.05 - $2.50
Volume1.06 million shs
Average Volume981,909 shs
Market Capitalization$90.41 million
P/E Ratio-1.91
Dividend YieldN/A
Beta0.49
SCYNEXIS logoSCYNEXIS, Inc., a drug development company, develops and commercializes anti-infectives to address unmet therapeutic needs. It is developing its lead product candidate, SCY-078, as a novel oral and intravenous drug for the treatment of various fungal infections, including serious and life-threatening invasive fungal infections. The company also develops SCY-078, which is in various Phase I studies for the oral and intravenous formulations, as well as has completed Phase II study as a step-down therapy in patients with invasive candidiasis and vulvovaginal candidiasis. It has research collaborations with Merck Sharp & Dohme Corp. and R-Pharm, CJSC, to develop and commercialize rights for SCY-078. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was founded in 1999 and is headquartered in Jersey City, New Jersey.

Receive SCYX News and Ratings via Email

Sign-up to receive the latest news and ratings for SCYX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SCYX
CUSIPN/A
Phone201-884-5485

Debt

Debt-to-Equity Ratio0.30
Current Ratio5.93
Quick Ratio5.93

Price-To-Earnings

Trailing P/E Ratio-1.91
Forward P/E Ratio-3.02
P/E GrowthN/A

Sales & Book Value

Annual Sales$260,000.00
Price / Sales347.70
Cash FlowN/A
Price / CashN/A
Book Value$0.74 per share
Price / Book2.61

Profitability

EPS (Most Recent Fiscal Year)($1.01)
Net Income$-25,060,000.00
Net Margins-9,450.00%
Return on Equity-78.78%
Return on Assets-43.38%

Miscellaneous

Employees19
Outstanding Shares46,840,000
Market Cap$90.41

The Truth About Cryptocurrencies

SCYNEXIS (NASDAQ:SCYX) Frequently Asked Questions

What is SCYNEXIS's stock symbol?

SCYNEXIS trades on the NASDAQ under the ticker symbol "SCYX."

How were SCYNEXIS's earnings last quarter?

SCYNEXIS Inc (NASDAQ:SCYX) posted its earnings results on Tuesday, May, 8th. The company reported ($0.12) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.18) by $0.06. The business had revenue of $0.06 million for the quarter, compared to analysts' expectations of $0.10 million. SCYNEXIS had a negative net margin of 9,450.00% and a negative return on equity of 78.78%. View SCYNEXIS's Earnings History.

What price target have analysts set for SCYX?

8 Wall Street analysts have issued twelve-month price targets for SCYNEXIS's stock. Their predictions range from $4.00 to $9.00. On average, they anticipate SCYNEXIS's stock price to reach $5.6250 in the next year. This suggests a possible upside of 191.5% from the stock's current price. View Analyst Ratings for SCYNEXIS.

What is the consensus analysts' recommendation for SCYNEXIS?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SCYNEXIS in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Who are some of SCYNEXIS's key competitors?

Who are SCYNEXIS's key executives?

SCYNEXIS's management team includes the folowing people:
  • Dr. Marco Taglietti, Chief Exec. Officer, Pres and Director (Age 58)
  • Mr. Eric Francois, Chief Financial Officer (Age 43)
  • Mr. David Gonzalez Angulo M.D., Chief Medical Officer (Age 53)
  • Mr. Scott Sukenick J.D., Gen. Counsel
  • Dr. Rajeshwar Motheram Ph.D., VP of Pharmaceutical Devel.

Has SCYNEXIS been receiving favorable news coverage?

Media headlines about SCYX stock have been trending somewhat positive recently, Accern reports. The research group identifies negative and positive news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. SCYNEXIS earned a media sentiment score of 0.08 on Accern's scale. They also assigned news stories about the company an impact score of 45.21 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

How do I buy shares of SCYNEXIS?

Shares of SCYX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is SCYNEXIS's stock price today?

One share of SCYX stock can currently be purchased for approximately $1.93.

How big of a company is SCYNEXIS?

SCYNEXIS has a market capitalization of $90.41 million and generates $260,000.00 in revenue each year. The company earns $-25,060,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis. SCYNEXIS employs 19 workers across the globe.

How can I contact SCYNEXIS?

SCYNEXIS's mailing address is 101 HUDSON STREET SUITE 3610, JERSEY CITY NJ, 07302. The company can be reached via phone at 201-884-5485 or via email at [email protected]


MarketBeat Community Rating for SCYNEXIS (NASDAQ SCYX)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  265 (Vote Outperform)
Underperform Votes:  119 (Vote Underperform)
Total Votes:  384
MarketBeat's community ratings are surveys of what our community members think about SCYNEXIS and other stocks. Vote "Outperform" if you believe SCYX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SCYX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.